Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases

Multidrug resistant tuberculosis (MDR-TB) is an increasing problem in many parts of the world and in Norway the increase has been substantial since 1998. New therapies for MDR-TB have not been introduced since the fluoroquinolones in the 1970s. The cure rate of this disease has been reported to be l...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2006-02, Vol.52 (2), p.92-96
Main Authors: von der Lippe, Bent, Sandven, Per, Brubakk, Oddbjørn
Format: Article
Language:English
Subjects:
Acetamides - adverse effects
Acetamides - standards
Acetamides - therapeutic use
Adult
Anemia - chemically induced
Anti-Infective Agents - adverse effects
Anti-Infective Agents - standards
Anti-Infective Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial diseases
Biological and medical sciences
Bone Marrow Diseases - chemically induced
Drug Therapy, Combination
Female
General aspects
Human bacterial diseases
Humans
Infectious diseases
Linezolid
Male
MDR-TB
Medical sciences
Microbial Sensitivity Tests - methods
Middle Aged
Myelosuppression
Oxazolidinones - adverse effects
Oxazolidinones - standards
Oxazolidinones - therapeutic use
Peripheral Nervous System Diseases - chemically induced
Peripheral neuropathy
Pharmacology. Drug treatments
Treatment Outcome
Tuberculosis and atypical mycobacterial infections
Tuberculosis, Multidrug-Resistant - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multidrug resistant tuberculosis (MDR-TB) is an increasing problem in many parts of the world and in Norway the increase has been substantial since 1998. New therapies for MDR-TB have not been introduced since the fluoroquinolones in the 1970s. The cure rate of this disease has been reported to be lower than for non-drug resistant TB, and the use of new experimental drugs in combination therapy is warranted. Ten consecutive patients with culture proven MDR-TB were treated with the novel antibiotic drug linezolid in combination regimens for 6–40 (median 17) weeks and followed up 11–50 (median 24) months after end of treatment. All strains were sensitive to linezolid with MIC
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2005.04.007